
Demand for weight loss drugs is becoming unsustainable, say pharmacists
The National Pharmacy Association (NPA) said supply problems could encourage people to turn to unregulated online sources, despite the risks involved.
The number of people in the UK using drugs such as Wegovy and Mounjaro has soared to well above a million, with most patients paying to get them privately.
During April, 1.6m packs of Mounjaro and Wegovy were bought in Britain, with the number thought to correlate closely with the number of people using them.
'Spiralling demand for weight loss medication risks going far beyond what is clinically deliverable', the NPA said.
The drugs might need to be reserved for those in greatest need because they are so overweight instead of being given to the 'worried well', it added.
New polling has found that 21% of Britons have tried to get hold of the medications over the past year, a figure that rises to 35% among 18- to 34-year-olds.
The same survey found that 41% of all age groups would use them if they were free on the NHS. This figure rose to 64% among those aged 25-34.
Savanta interviewed a representative sample of 2,002 adults aged 18 or over online from 20-23 June for the NPA, which represents 6,000 independent pharmacies.
'Weight loss jabs are one of the biggest drug innovations this century but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it,' said Olivier Picard, the NPA's chair.
'It's clear from this polling that more people are interested in getting weight loss jabs than can benefit from weight loss medication.'
Supply of the medicines has been hit by shortages in some parts of the UK, including for higher doses of Mounjaro, the NPA said. Supply has been restricted to some pharmacies, which has stopped some new patients from going on to the drugs.
The Medicines and Healthcare products Regulatory Agency, the UK's drugs watchdog, has warned patients to obtain the drugs only with a doctor's prescription, and not from beauty parlours or websites.
A Department of Health spokesperson said more people would be able to obtain 'revolutionary' weight loss jabs over the next few years.
'Weight loss drugs are a powerful tool in tackling the obesity crisis head-on as part of our 10-year health plan', they added.
'This government is committed to ensuring that more people have access to these revolutionary drugs when needed, and crucially that they are able to do so in a safe and controlled way. We will ensure that those most in need will receive treatment first.'
About 220,000 people in England are due to be offered tirzepatide, a diabetes drug that promotes weight loss, over the next three years.
Pharmacies already provide about 85% of all weight loss drugs and need to be closely involved in the expansion of access, Picard added.
'The government should use the massive untapped expertise and skills of pharmacists to help speed up the NHS's weight loss medication programme to millions of the most in need patients,' he said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Scotsman
4 hours ago
- Scotsman
From pints to PJs: why more adults are choosing nights in over nights out
More than half of adults are staying in more often than they were two years ago Sign up to our daily newsletter Sign up Thank you for signing up! Did you know with a Digital Subscription to Edinburgh News, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... A majority of adults are increasingly swapping nights on the town for quiet evenings in front of the TV, according to fascinating new research into the nation's social habits. The study, conducted by online weight loss clinic found more than half of people (56%) stay in more often now than they did two years ago, as trends switch amid a changing cultural and economic landscape. Advertisement Hide Ad Advertisement Hide Ad Body image is a key factor, data shows, with over a third (37%) of adults admitting they avoid going out due to how they feel about their appearance. Weight loss injection terms searched in Google more than six million times in the UK in June The findings echo UK Parliament data which show 63.8% of UK adults are living with an unhealthy weight - one of the highest rates in Europe. With obesity classified by the World Health Organisation (WHO) as a chronic and complex disease, the knock-on effect on self-esteem and social behaviour is becoming increasingly clear. As people retreat from social settings, the data reveals an impact on dating culture. Advertisement Hide Ad Advertisement Hide Ad Over half (58%) of those surveyed say they feel pressure to look a certain way when socialising, while fewer than half (48%) report feeling confident when dating. These shifts are also reflected in changing lifestyle habits more broadly. More than half (55%) of adults say they are now drinking less than they were two years ago - a figure that's likely linked to a reduction in nights out and a preference for staying in. At the same time, people are increasingly seeking solutions, with data showing three in ten (30%) adults are now open to using weight loss medication to help regain confidence. Advertisement Hide Ad Advertisement Hide Ad Searches for weight loss injection treatments like Mounjaro and Wegovy, were searched on Google in the UK more than 6.4million times last month alone. The nationwide survey of 1,000 adults was conducted by myBMI, a weight loss clinic built by medical specialists to give customers access to the most effective prescription weight loss treatments. John Campbell, prescribing pharmacist and weight loss expert at myBMI, said: 'This research highlights the wider impact weight-related issues are having on people's daily lives - not just from a health perspective, but socially and psychologically too. 'We're seeing a growing number of adults staying home more often due to low body confidence, which is also affecting their dating lives, social relationships and even drinking habits.' Advertisement Hide Ad Advertisement Hide Ad John added: "As awareness around medical weight loss treatments grows, more people are now actively seeking support to address the underlying causes. 'At myBMI, all prescribing pharmacists are registered with the GpHC and specially trained to support patients at all stages of their weight loss journey. "Our goal is to ensure patients have safe, informed access to the most effective support available - helping them to take control of their health and regain confidence in their everyday lives.'


BBC News
4 hours ago
- BBC News
Wegovy maker Novo Nordisk warns of slower profits as rivals bite
The Danish-maker of Wegovy and Ozempic has warned that its full-year sales and profits will not grow as quickly as expected as more "knock-off" weight-loss drugs Nordisk's share price tumbled by more than 20% as it cut its outlook and named a new chief executive to replace Lars Fruergaard Jørgensen, whose surprise exit was announced in Mike Doustdar, currently vice president of Novo Nordisk's international business, will take over on 7 August. As well as slower-than-forecast growth for Wegovy in the US obesity market, Novo Nordisk also said that sales of Ozempic to Americans with diabetes would be lower. Novo Nordisk has seen its market value tumble as other weight-loss treatments have come onto the its trading update, Novo Nordisk claimed that since May more "unsafe and unlawful" drugs have been released. The company said it "is pursuing multiple strategies, including litigation, to protect patients from knock-off 'semaglutide' drugs".Semaglutide injections are used to treat diabetes but, in recent years, have become wildly popular with people looking to lose weight, especially after the enforced lockdowns of Covid. While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts said the company had been too slow to pursue the market for people willing to pay for its weight-loss treatments. Markus Manns, a portfolio manager at Union Investment, which is a shareholder in Novo Nordisk, said that its "problems are much deeper" than Wegovy in the US and extend to the international market."Novo has underestimated the self-pay market in obesity and just recently started to focus on this important patient segment," he Manns also described the cuts to Novo's growth outlook as "a shocker". Full-year profit is now expected to expand by 10% and 16%, down from an increase of between 16% and 24% predicted in are predicted to increase by between 8% and 14%. In May, Novo forecast growth of between 13% and 21%.Benjamin Jackson, an analyst at Jeffries, questioned why Novo Nordisk has decided to appoint an internal candidate to replace Mr Jø Doustdar first joined Novo Nordisk in 1992. The company said that he had been appointed "as the result of a comprehensive process that included external and internal candidates".But Mr Jackson said: "We are surprised by the appointment of Mike Doustdar as chief executive with feedback suggesting an external candidate may have been preferred."


Reuters
5 hours ago
- Reuters
VIEW Reaction to new Novo Nordisk CEO, profit warning
July 29 (Reuters) - Novo Nordisk ( opens new tab on Tuesday appointed insider Mike Doustdar as its new chief executive after the Danish obesity drug maker cut its full year outlook for the second time in 2025, sending its shares tumbling. Here are some reactions from market analysts and investors: MARKUS MANNS, A PORTFOLIO MANAGER AT MUTUAL FUNDS FIRM UNION INVESTMENT AND A SHAREHOLDER IN THE COMPANY: "While most people had expected Novo to just trim the top end of the guidance, the magnitude of the guidance cut is a shocker. Novo's problems are much deeper than just compunded Wegovy in the U.S. and extend to the international Wegovy franchise and even to Ozempic in diabetes. Novo has underestimated the self pay market in obesity and just recently started to focus on this important patient segment." JEFFERIES ANALYST BENJAMIN JACKSON ON NEW CEO: "We are surprised by the appointment of Mike Doustdar as CEO, with feedback suggesting an external candidate may have been preferred." ANALYSTS ON THE PROFIT WARNING: "Lowered guidance (is) a reflection of growth expectations in H2'25 for both Wegovy and Ozempic." CITI ANALYSTS ON THE PROFIT WARNING: "We caution against over-reading into Novo's assessment, given tirzepatide's script strength pre-July 1st has been robust and Lilly may have had a more conservative outlook on expectations when giving its own 2025 guidance. Thus, we remain buyers on weakness." ANGELO MEDA, PORTFOLIO MANAGER AND HEAD OF EQUITIES AT BANOR SIM IN MILAN: "The biggest concern is the illegal channel siphoning away market share—something that's hard to quantify. Rebuilding trust will take time."